Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
Open accessAbstract
Summary: Objective: Recombinant human leptin (metreleptin) improves glycaemia and hypertriglyceridaemia in patients with generalized lipodystrophy; antibody development with in vitro neutralizing activity has been reported. We aimed to characterize antimetreleptin antibody development, including in vitro neutralizing activity. Design: Two randomized controlled studies in patients with obesity (twice‐daily metreleptin ± pramlintide for 20–52 weeks; 2006–2009); two long‐term, open‐label studies in patients with lipodystrophy (once‐daily or twice‐daily metreleptin for 2 months to 12·3 years; 2000–2014). Patients: A total of 579 metreleptin‐treated patients with obesity and 134 metreleptin‐treated patients with lipodystrophy (antibody/neutralizing activity data: n = 105). Measurements: Antimetreleptin antibodies, in vitro neutralizing activity. Results: Antimetreleptin antibodies developed in most patients (obese: 96–100%; lipodystrophy: 86–92%). Peak antibody titers (approximately 1:125 to 1:3125) generally occurred within 4–6 months and decreased with continued therapy (lipodystrophy). Antibody development did not adversely impact efficacy or safety (patients with obesity), except for inflammatory injection site reactions, but was associated with elevated leptin concentrations. Three patients with obesity developed in vitro neutralizing activity coincident with weight gain. Weight later returned to baseline in one patient despite persistent neutralizing activity. Four patients with generalized lipodystrophy developed in vitro neutralizing activity concurrent with worsened metabolic control; two with confounding comorbidities had sepsis. One patient with lipodystrophy had resolution of neutralizing activity on metreleptin. Conclusions: Development of in vitro neutralizing activity could be associated with loss of efficacy but has not been consistently associated with adverse clinical consequences. Whether neutralization of endogenous leptin with clinical consequences occurs remains unclear.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin.
“Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin [86].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · see citing works
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326 · see citing works
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422 · see citing works
Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15693 · Cited by 1,359 · see citing works
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · see citing works
Self-citationFarooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105 · see citing works
Acquired and Inherited Lipodystrophies
Garg, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra025261 · Cited by 939 · see citing works
Lipodystrophies: Genetic and Acquired Body Fat Disorders
Garg, A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1159 · Cited by 556 · see citing works
Licinio, J., Caglayan, S., Ozata, M., Yildiz, B. O., de Miranda, P. B., O'Kirwan, F., Whitby, R., Liang, L., Cohen, P., Bhasin, S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308767101 · Cited by 505 · see citing works
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · see citing works
Self-citationSerum Adiponectin and Leptin Levels in Patients with Lipodystrophies
Haque, W. A., Shimomura, I., Matsuzawa, Y., & Garg, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8624 · Cited by 394 · see citing works
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372 · see citing works
Ravussin, É., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 335 · see citing works
Self-citationProcaccini, C., Jirillo, E., & Matarese, G. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.012 · Cited by 299 · see citing works
20 YEARS OF LEPTIN: Leptin at 20: an overview
Friedman, J. M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0405 · Cited by 249 · see citing works
Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226 · see citing works
Self-citationEfficacy of leptin therapy in the different forms of human lipodystrophy
Chong, A. Y., Lupsa, B. C., Cochran, E. K., & Görden, P. (2009) · Diabetologia · doi:10.1007/s00125-009-1502-9 · Cited by 175 · see citing works
Self-citationClinical Effects of Long-Term Metreleptin Treatment in Patients With Lipodystrophy
Chan, J. L., Lutz, K., Cochran, E. K., Huang, W., Peters, Y., Weyer, C., & Görden, P. (2011) · Endocrine Practice · doi:10.4158/ep11229.or · Cited by 145 · see citing works
Self-citationClinical Classification and Treatment of Congenital and Acquired Lipodystrophy
Chan, J. L., & Oral, E. A. (2010) · Endocrine Practice · doi:10.4158/ep09154.ra · Cited by 93 · see citing works
Self-citationBeltrand, J., Beregszàszi, M., Chevenne, D., Sebag, G. H., de Kerdanet, M., Huet, F., Polak, M., Tubiana‐Rufi, N., Lacombe, D., Paoli, A. M. D., et al. (2007) · PEDIATRICS · doi:10.1542/peds.2006-3165 · Cited by 89 · see citing works
Beltrand, J., Lahlou, N., Charpentier, T. L., Sebag, G. H., Leka, S., Polak, M., Tubiana‐Rufi, N., Lacombe, D., de Kerdanet, M., Huet, F., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1027 · Cited by 57 · see citing works
Altered Cell Surface Expression and Signaling of Leptin Receptors Containing the fattyMutation
Crouse, J. A., Elliott, G. E., Burgess, T. L., Chiu, L., Bennett, L., Moore, J., Nicolson, M. A., & Pacifici, R. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18365 · Cited by 33 · see citing works
Immunogenicity of xenopeptide hormone therapies
Schnabel, C. A., Fineberg, S. E., & Kim, D. D. H. (2006) · Peptides · doi:10.1016/j.peptides.2006.01.019 · Cited by 24 · see citing works
Wang, Y., & Heilig, J. S. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.06.018 · Cited by 19 · see citing works
Self-citationWeeraratne, D. K., Kuck, A. J., Chirmule, N. B., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00435-12 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Leptin and Obesity: Role and clinical implication.
Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.585887 · Cited by 1,121 · see citing works
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · see citing works
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462 · see citing works
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343 · see citing works
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299 · see citing works
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232 · see citing works
Effects of Metreleptin in Pediatric Patients With Lipodystrophy
Brown, R. J., Meehan, C. A., Cochran, E., Rother, K. I., Kleiner, D. E., Walter, M., & Gorden, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3628 · Cited by 65 · see citing works
Self-citation
- Authors
- Chan, J. L., Koda, J., Heilig, J. S., Cochran, E. K., Gorden, P., Oral, E. A., & Brown, R. J.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- AstraZeneca San Diego CA USA
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD USA
- University of Michigan (US)
- Corresponding author
- Brown, Rebecca J.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2016-02-02
- Volume
- 85
- Issue
- 1
- Pages
- 137-149
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- PMC
- PMC4875885
- OpenAlex
- W2244529015
- Cited by
- 72
- References
- 25
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 9 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 3 · 2016: 3
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca
- Bristol-Myers Squibb
- Amylin Pharmaceuticals
- National Institutes of Health (UL1TR000433)
- Topics
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- metreleptin, recombinant human leptin, immunogenicity, neutralizing antibodies, generalized lipodystrophy, obesity, pramlintide, hypertriglyceridemia, glycemic control, weight gain, injection site reactions, sepsis
- MeSH terms
- Adolescent, Adult, Antibodies, Antibody Formation, Child, Female, Humans, Lipodystrophy, Male, Middle Aged, Obesity, Leptin, Immunogenetic Phenomena, Young Adult, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
